# Study of ARO-APOC3 in Adults With Dyslipidemia

Study · id `cardio:ct-nct05413135` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05413135](<https://clinicaltrials.gov/study/NCT05413135>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05413135

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 418 participants.

## Technical summary

Registry record NCT05413135. Allocation not applicable; no masking; primary purpose treatment. Start 2022-07-07 (actual); primary completion 2025-09-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 418 participants (enrolled count; ClinicalTrials.gov record NCT05413135, source copy `cardio:ctgov-nct05413135-2026-05-12`, retrieved 2026-10-31)
- Started: 2022-07-07 (actual) (ClinicalTrials.gov record NCT05413135, source copy `cardio:ctgov-nct05413135-2026-05-12`, retrieved 2026-10-31)
- Primary completion: 2025-09-22 (actual) (ClinicalTrials.gov record NCT05413135, source copy `cardio:ctgov-nct05413135-2026-05-12`, retrieved 2026-10-31)
- Completion: 2025-09-22 (actual) (ClinicalTrials.gov record NCT05413135, source copy `cardio:ctgov-nct05413135-2026-05-12`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; Hungary; Netherlands; New Zealand; Poland (ClinicalTrials.gov record NCT05413135, source copy `cardio:ctgov-nct05413135-2026-05-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05413135-2026-05-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of ARO-APOC3 in Adults With Dyslipidemia
- Condition: Dyslipidemias
- Intervention (Drug): ARO-APOC3
- Lead sponsor: Arrowhead Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Arrowhead Pharmaceuticals (`cardio:org-arrowhead-pharmaceuticals`)

## Provenance

Content hash: eb642da9b7dcde3b4f5d9eee41b6b7ac908b4912e170d447d350df171aefa30f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
